Berkeley, California (EastBayDaily) — In an effort towards advancing knowledge through quality education and engagement, UroToday, the leading U.S.-based urology website, presents exclusive videos on the treatment of metastatic castrate-resistant prostate cancer (mCRPC).
These video lectures, offered by leaders across the broad spectrum of the urology and GU oncology specialties, are published in various channels in Urology TUBEâ¢ — including the mCRPC Live, the Immunotherapy Live and mCRPC Radiotherapy Live channels. Urology TUBE is a rich media, content distribution portal offering a simplified interface designed to provide easier access to video content channels. To retain its ease of use for their long-term readership, it is structured to parallel the disease topics article sections on UroToday.
“UroToday delivers relevant, factual, online content that urologists have been accessing since we launched in 2003. UroToday continues to grow because we have consistently delivered accurate information allowing urologists to stay up to date in this diverse and rapidly evolving field,” says Gina B. Carithers, Founder and CEO of UroToday.
Some of the recent highlights of available content in Urology TUBE include: Paul R. Sieber, MD, FACS from Lancaster Urology presents two mCRPC patient cases and demonstrates the individualized treatment process of care unique to each patient. Oliver Sartor, MD of Tulane Cancer Center discusses a Lancet Oncology article that examines the effects of radium-223 dichloride on symptomatic skeletal events in patients with CRPC and bone metastases. He also walks us through his approach to treating a patient with mCRPC, who is now experiencing mild pain due to his bone metastases. In an interview from the AUA Annual Meeting, Michael S. Cookson, MD, MMHC from the University of Oklahoma College of Medicine presents an update on the AUA guidelines for the treatment of mCRPC. In an interview from the annual meeting of the American Society of Clinical Oncology (ASCO), Christopher Sweeney, MD from Dana-Farber Cancer Institute discusses the results of an ECOG-led phase III randomized trial, focusing on the impact on overall survival with chemohormonal therapy versus hormonal therapy for hormone-sensitive mCRPC patients.
About UroToday® UroToday is an online medical resource that focuses on genitourinary cancers, as well as all other urologic health conditions impacting men and women. Based in Berkeley, California, the website was founded in 2003 by Gina Carithers, CEO of its parent company, Digital Science Press, Inc. With more than 250 new content items posted every week, http://www.urotoday.com is the world’s largest and most comprehensive online urology-oncology resource and is accessible, at no charge, to readers in the United States and around the globe.